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Summary Key Points 
• Seasonal influenza activity in the United States increased again in this week’s 
FluView report.  
• Puerto Rico and 48 states continue to report widespread geographic activity this 
week. (Oregon went from widespread to regional geographic activity.) 
• While flu activity appears to be declining along the West coast, overall, influenza-
like-illness increased again nationally.  
• The proportion of people seeing their health care provider for influenza-like-illness 
(ILI) increased from last week’s report (from 6.6% to 7.1%); New York City, the 
District of Columbia, and 42 states (up from 39 states) experienced high ILI 
activity. 
• This is higher than ILI peaks seen during recent H3N2 seasons and actually the 
highest level of ILI recorded since the 2009 H1N1 pandemic, which peaked at 7.7% 
ILI.  
• This is the 10th week that ILI has been at or above the national baseline.  
• By this measure, the past five seasons have averaged 16 weeks, with the longest 
season lasting 20 weeks.  
• It’s likely there will be significant flu activity for many weeks to come. 
• Flu activity indicators are notable for the sheer volume and intensity of flu that is 
occurring in most of the country at the same time. 
• The timing and rate of increase this season was similar to what was seen during the 
2012-2013 and 2014-2015 seasons, but ILI is now higher than it was at the peak of 
those two seasons (7.1% versus 6%). 
• It’s difficult to say how severe this season will be, but at this time hospitalization 
rates have surpassed what was reported during the same week in 2014-2015.  The 
2014-2015 season was a high severity H3N2-predominant season. 
• The highest hospitalization rate is among people 65 years and older (226.8 per 
100,000). This age group always has the highest hospitalization rate; higher than 
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the 214/100,000 rate that was reported for people 65 and older for 2014-15 during 
the same week.  
• If this current trend in hospitalization rates is maintained through the season, it is 
possible that the number of flu hospitalizations may well exceed 710,000, which is 
the high end of the estimated hospitalizations that have occurred in the United 
States since 2010. 
• The proportion of deaths attributed to pneumonia and influenza (P & I) is above the 
epidemic threshold, which means that more deaths are occurring due to pneumonia 
and influenza that would be expected at this time. 
• P & I has been above the epidemic threshold for 4 weeks. 
• Another 17 flu-related pediatric deaths were reported this week (one of which 
occurred during the 2015-2016 season) bringing the total number of flu-related 
pediatric deaths reported to CDC so far to 53. 
• Influenza A(H3N2) viruses continue to predominate but the proportion of influenza 
B viruses in increasing slightly. 
• H3N2-predominant seasons have been associated with more severe illness 
especially among people older than 65 years and children. 
• Vaccine effectiveness (VE) against H3N2 viruses in the past has also been relatively 
low. Effectiveness against H1N1 and influenza B viruses has been better. 
• The relatively lower vaccine effectiveness seen against H3N2 viruses may, in part, 
be caused by egg-adapted changes introduced when H3N2 viruses are optimized for 
growth in eggs, which is required for the egg-based production used to produce 
most U.S. flu vaccines.  
• CDC recommends a 3-pronged strategy to fight flu. 1. Take time to get a flu 
vaccine. 2, Take everyday preventive actions, including staying away from sick 
people, and 3, Take antiviral drugs if your doctor prescribes them. 
• It’s not too late to get vaccinated.  
• As long as flu viruses are circulating, vaccination should continue throughout the flu 
season, even in January or later even though protection against H3N2 viruses is 
typically lower than against other flu viruses.  
• There are many reasons to get a flu vaccine. 
1. While flu vaccine can vary in how well it works, it is the best way to prevent 
flu illness and serious flu complications, including those that can result in 
hospitalization. 
2. We cannot know which viruses will circulate over the season and which virus 
will predominate. Flu vaccine protects against three or four different flu 
viruses, depending on which vaccine you get.  
3. A 2017 study was the first of its kind to show that flu vaccination can 
significantly reduce a child’s risk of dying from influenza. 
4. Getting vaccinated yourself protects people around you, including those who 
are more vulnerable to serious flu illness, like babies and young children, 
older people, and people with certain chronic health conditions. 
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5. While flu vaccine is not perfect and some people who get vaccinated may still 
get flu, there is some data to suggest that flu vaccination may make illness 
milder. 
• While flu vaccine is the best way to prevent flu, influenza antiviral drugs are a 
second line of defense that can be used to treat flu illness. 
• Most people who are otherwise healthy and get the flu do not need to be treated 
with antiviral drugs, but some people are more likely to get very sick, especially the 
very young, the very old, pregnant women, and those with medical conditions that 
put them at high risk for developing severe infection. 
• CDC recommends prompt treatment with flu antiviral drugs for people who are very 
sick with flu symptoms or people who are at high risk of developing serious flu 
complications when they get flu symptoms. 
• The volume of flu the country is experiencing right now has led to spot shortages of 
flu vaccine, antiviral drugs and even tests to quickly diagnose flu. 
• People may need to be persistent to locate vaccine, antiviral drugs to fill a 
prescription. 
 
Flu & Sepsis 
• Also important to note, flu infection can be associated with sepsis, even in 
otherwise healthy people, and that is a life-threatening condition.  
• CDC has received reports from some state health departments of flu deaths 
associated with sepsis this season.  
• A recent CDC study found that 30% of pediatric death reports included sepsis listed 
as a complication. 
• More information about sepsis can be found at 
https://www.cdc.gov/sepsis/index.html 
 
Vaccine Availability 
• Manufacturers report having shipped more than 152.1 million doses of flu vaccine 
as of January 12, 2018. 
• The total projected supply of vaccine in the United States this season is between 
151 million and 166 million doses of flu vaccine. About 119 million doses will be 
quadrivalent vaccine. 
 
For Patients: 
CDC continues to recommend flu vaccination as the first line of defense against the flu. 
While some individual providers may be running low on flu vaccine at this point in the 
season, flu vaccine is available from a variety of providers throughout the country. Call 
your doctor, or use the flu vaccine finder to find where vaccine is available in your 
community.  
 
For Providers: 
CDC Influenza Division Key Points          
February 2, 2018 
4 
 
Flu vaccine is available, but providers may not be able to get every brand and/or 
presentation, and they may have to purchase from a different source.  Providers 
interested in purchasing vaccine should check the influenza vaccine tracking availability 
system (IVATS) available at:  https://www.izsummitpartners.org/ivats/. 
 
Antiviral Supply 
• CDC is in regular contact with influenza antiviral manufacturers regarding supply 
and other issues. 
• Some manufacturers are reporting delays in filling orders and CDC is aware of spot 
shortages of antiviral drugs specifically for oseltamivir suspension and generic 
oseltamivir capsules in some places experiencing high influenza activity.  
• CDC is working with manufacturers to address any existing gaps in the market. 
• Additionally, pharmacists should consider compounding oseltamivir suspension by 
using oseltamivir 75 mg capsules if suspension is not readily available for patients 
that need it. 
• Pharmacies and others attempting to make bulk purchases of influenza antiviral 
drugs may need to call more than one distributor or manufacturer to locate 
medications available for purchase in the short term. CDC has updated its antiviral 
drug supply web page with manufacturer information for inquires related to 
antiviral purchases/availability. 
• Individual patients seeking to fill an influenza antiviral prescription may want to call 
ahead to make sure their pharmacy has product on the shelf to fill their 
prescription. It may be necessary to call more than one pharmacy to locate these 
medications. 
• Antiviral drugs work better the earlier you begin taking them so prompt action is 
important. 
• For people who have flu and are at high risk of serious flu complications, treatment 
with an antiviral drug can mean the difference between having a milder illness and 
having a very serious illness that could result in a hospital stay. 
 
Supply of Flu Tests & Testing Guidance 
• CDC has received reports of spot shortages of some influenza tests, including Rapid 
Influenza Diagnostic Tests (RIDTs) and Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR). 
• These reports coincide with an ongoing intense and widespread seasonal influenza 
epidemic, during which spot shortage of flu vaccines and influenza antiviral 
medications also have been observed. 
o RIDTs are tests that can identify the presence of influenza A and B viral 
nucleoprotein antigens in respiratory specimens, and display the result. 
o While RIDTs can be important for diagnosis and treatment, how well they work 
can vary dramatically based on a number of factors. 
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o Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and other molecular 
assays can identify the presence of influenza viral RNA in respiratory specimens. 
• These test are generally much more reliable and are recommended by 
CDC for use on hospitalized patients. 
• According to CDC guidance, testing is not needed for all patients with signs and 
symptoms of influenza to make antiviral treatment decisions.  
• Once influenza activity has been documented in the community or geographic area, 
a clinical diagnosis of influenza can be made for outpatients with signs and 
symptoms consistent with suspected influenza, especially during periods of peak 
influenza activity in the community. 
• Guidance for Clinicians on the Use of RT-PCR and Other Molecular Assays for 
Diagnosis of Influenza Virus Infection is available at 
https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm . 
• Guidance on the use of RIDTs is available at 
https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm . 
 
Influenza Treatment: Antiviral Medications 
• Antiviral drugs are prescription medicines (pills, liquid or an inhaled powder) and 
are not available over the counter.  
• Influenza antiviral drugs are the only drugs approved to treat influenza infection. 
• Antiviral drugs are different from antibiotics. Antiviral drugs fight viruses (like flu 
viruses) in your body; antibiotics fight infections in your body that are caused by 
bacteria.  
• Antiviral drugs can make flu illness milder and shorten the time you are sick.  
• There also are data showing that antiviral drugs may prevent serious flu 
complications such as pneumonia and hospitalizations in outpatients, and reduce 
mortality and length of stay in hospitalized patients.  
o For example, in 2015, a CDC study found that early treatment of flu-
hospitalized people 65 and older with flu antiviral medications cut the 
duration of their hospital stay and reduced their risk of needing extended 
care after discharge.  
o This study entitled “Impact of Prompt Influenza Antiviral Treatment on 
Extended Care Needs After Influenza Hospitalization Among Community-
Dwelling Older Adults” by Sandra Chaves et al. is available from the Clinical 
Infectious Diseases journal website at 
http://cid.oxfordjournals.org/content/early/2015/09/01/cid.civ733 .  
• Antiviral drugs work best when started within two days of symptoms first 
appearing, but there are data to suggest they can still be beneficial in very ill 
patients even up to five days after getting sick. This would be especially important 
for a person who is at high risk of serious flu complications and who is very sick.  
• Three FDA-approved influenza antiviral drugs are recommended for use in the 
United States during the 2017-2018 influenza season: oseltamivir (Tamiflu® and 
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generic formulations), zanamivir (Relenza®), and peramivir (Rapivab®). Generic 
formulations of oseltamivir became available commercially last season. 
• Antiviral drugs are not a substitute for getting a flu vaccine. The flu vaccine is the 
best way modern medicine currently has to prevent this potentially serious disease.  
• See Influenza Antiviral Medications: Summary for Clinicians on the CDC web site for 
additional information.  
 
Antiviral Side Effects Summary 
• With all medications there are reported side effects: 
 
Oral oseltamivir 
• This medication can be used for treatment of people  of all ages 
• Adverse reactions to oseltamivir include nausea, vomiting and headache. 
• There have also been some post-marketing reports of serious skin reactions and 
sporadic, transient neuropsychiatric events. 
 
Inhaled zanamivir 
• This drug can be used for treatment in those 7 years and older; however it isn’t 
recommended for use in people with underlying respiratory diseases (e.g., asthma, 
COPD), nor is it recommended for patients hospitalized with influenza 
• Zanamivir can be used for chemo-prophylaxis of those 5 years and older; however 
they shouldn’t use it if they have they have underlying respiratory diseases (e.g., 
asthma, COPD) 
• Allergic reactions have been reported to throat or facial swelling and a skin rash. 
• Some adverse reactions to zanamivir include bronchospasm, especially in the 
setting of underlying airways disease; sinusitis, dizziness, and ear, nose and throat 
infections. 
• There were some post-marketing reports of serious skin reactions and sporadic, 
transient neuropsychiatric events 
 
Intravenous peramivir 
• This drug can be used for treatment of those 2 years and older 
• Some adverse reactions to peramivir include diarrhea. 
• There were some post-marketing reports of serious skin reactions and sporadic, 
transient neuropsychiatric events 
 
For more information on safety, effectiveness and dosing for oral oseltamivir, inhaled 
zanamivir, and intravenous peramivir, visit the Food and Drugs Administration (FDA) 
website https://www.fda.gov/Drugs/DrugSafety/ and/or consult the product package 
inserts. 
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Communications Activities 
• On December 27, 2017, CDC issued a Health Advisory 
(https://emergency.cdc.gov/han/han00409.asp ) through the Health Alert Network, 
providing notice about 1) increased influenza A(H3N2) activity and its clinical 
implications, 2) a summary of influenza antiviral drug treatment recommendations, 
3) an update about approved treatment drugs and supply this season, and 4) 
background information for patients about influenza treatment.  
• The transcript for a January 12, 2018, is available at 
https://www.cdc.gov/media/releases/2018/t0112-widespread-flu-activity.html.  
• The video of a January 16, 2017, Public Health Grand Rounds on the influenza is 
available at https://www.cdc.gov/cdcgrandrounds/archives/2018/January2018.htm. 
• A transcript for a telebriefing held on January 26, 2018 is available at 
https://www.cdc.gov/media/releases/2018/t0126-flu-update-activity.html.  
• On Friday, February 2, 2018, a telebriefing was held. A transcript will be available 
at https://www.cdc.gov/media/index.html .  
Vaccine Effectiveness 
• While vaccine effectiveness can vary, a study that pooled influenza vaccine 
effectiveness estimates from 2007 to 2015 by virus type and subtype found that: 
o Multi-year pooled vaccine effectiveness against influenza B viruses was 54%;  
o Multi-year pooled vaccine effectiveness against influenza A(H1N1)pdm09 
viruses was 61%;  
o Multi-year pooled vaccine effectiveness against H3N2 viruses was 33%. 
o Belongia EA, Simpson, MD, King JF, Sundaran ME, Kelley NS, 
Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by 
subtype: a systematic review and meta-analysis of test-negative 
design studies. Lancet Infect Dis. 2016; 16(8):942-51. 
• It is important to note that during seasons when the majority of circulating viruses 
are very different from a vaccine virus, vaccine effectiveness can be further 
reduced. 
• Two types of genetic changes can impact the similarity between a vaccine virus and 
circulating seasonal viruses. 
1. Influenza viruses constantly undergo small genetic changes. These genetic 
changes can sometimes result in antigenic changes. This is called “antigenic 
drift.” (Circulating viruses “drift” away from what is included in the vaccine.)  
▪ For more information on antigenic changes, see CDC’s Antigenic 
Characterization page at 
https://www.cdc.gov/flu/professionals/laboratory/antigenic.htm.  
2. Another type of change that can happen is that genetic changes occur when 
influenza viruses are grown in eggs, which is required for most U.S. flu 
vaccines.  
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▪ These genetic changes (called “egg-adapted” changes) may have 
antigenic (or immunogenic) implications that may impact how well the 
vaccine works.  
▪ Egg-adapted changes that are associated with antigenic changes 
occur more often in H3N2 viruses.  
• The lower vaccine effectiveness seen against H3N2 viruses during seasons when no 
antigenic drift has occurred may, in part, be caused by egg-adapted changes. 
• Most U.S. flu vaccines are produced using egg-based technology. 
• There are two flu vaccines in the United States that are not grown in eggs: 
recombinant influenza vaccine (Flublok) and cell-grown influenza vaccine 
(Flucelvax).  
o Recombinant vaccine is made by growing a certain protein from a 
naturally occurring (“wild type”) recommended vaccine virus in insect 
cells. 
o This season, Flucelvax is being made using a cell-grown H3N2 candidate 
vaccine virus for the first time.  
o Previously Flucelvax had been produced using cell-based technology but 
with candidate vaccine viruses isolated in eggs per FDA regulatory 
requirements.  
o On August 31, 2016, FDA approved the use of cell-isolated candidate 
vaccine viruses in the production of Flucelvax, the only licensed cell-based 
flu vaccine in the United States. 
• For recombinant and cell-grown vaccines, the H3N2 components are genetically 
more similar to circulating H3N2 viruses than the egg-adapted viruses 
recommended for egg-based manufacturing. 
• At this time there is insufficient data to determine whether cell-based or 
recombinant vaccine are more effective than egg-based vaccine. 
• Additional data is needed (including vaccine effectiveness data) before policy 
decisions on this topic could be considered. 
 
Canadian Study of Vaccine Effectiveness 
• CDC conducts vaccine effectiveness studies each season. 
• For the current season, CDC will collect finalized data from its 5 U.S. vaccine 
effectiveness (VE) network study sites in early February, 2018 and analyze that 
data with results expected in mid-February. 
• A study in Canada this season showed that VE against H3N2 is lower than observed 
last season in Canada and the U.S., and lower than what would be expected in the 
absence of significant antigenic drift. VE against influenza B is better, which is 
consistent with expectations. 
• It’s possible that we could see similar estimates in the U.S.  
• Sometimes Canadian and U.S. VE estimates have been similar; during other 
seasons they have differed. 
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• H3N2 viruses are notoriously problematic and vaccine effectiveness against these 
viruses is always lower than for other vaccine viruses. 
• There are a number of possible reasons for the intense flu season and why we 
might see lower than expected VE; these are the focus of ongoing investigation.  
o Reasons could include host factors (how a person responds to vaccine or 
infection); the virus (and changes in viruses over time) and the difficulties 
with H3N2 vaccine viruses. 
o We are looking into all these possibilities. 
• Yearly monitoring of VE is critical so that we can identify vaccine issues that need to 
be understood and corrected.  
• These findings underscore the need for better flu vaccines, but also highlight the 
need for more scientific data to help guide efforts to improve flu vaccines. 
FluView Activity Update (Key Flu Indicators)  
Influenza activity increased again according to the latest FluView report. All U.S. states 
but Hawaii and Oregon continue to report widespread flu activity and the number of states 
experiencing high influenza-like illness (ILI) activity increased from 39 states plus New 
York City and Puerto Rico to 42 states plus New York City and the District of Columbia. At 
7.1 percent, influenza-like-illness (LI) is approaching the 7.7% peak of the 2009 
pandemic. The overall hospitalization rate is higher than overall hospitalization rate 
reported during the same week of the 2014-2015 season, the most severe season in 
recent years. CDC also is reporting an additional 17 flu-related pediatric deaths during 
week 4, including one of which occurred during the 2015-2016 season, bringing the total 
number of flu-related pediatric deaths reported this season to 53 so far. Flu activity is 
likely to remain elevated for several more weeks.  
 
CDC continues to recommend influenza vaccination for all persons 6 months of age and 
older as flu viruses are likely to continue circulating for weeks. In addition, in the context 
of widespread influenza activity, CDC is reminding clinicians and the public about the 
importance of antiviral medications for prompt treatment of influenza with antiviral 
medications in people who are severely ill and people who are at high risk of serious flu 
complications who develop flu symptoms. Below is a summary of the key flu indicators for 
the week ending January 27, 2018 (week 4): 
 
• Influenza-like Illness Surveillance: For the week ending January 27, the 
proportion of people seeing their health care provider for influenza-like illness (ILI) was 
7.1%, which is above the national baseline of 2.2% and is the highest ILI 
percentage recorded since the 2009 pandemic. All 10 regions reported a proportion 
of outpatient visits for ILI at or above their region-specific baseline levels. ILI has 
been at or above the national baseline for 10 weeks so far this season. Over the 
past five seasons, ILI has remained at or above baseline for 16 weeks on average. 
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o Additional ILINet data, including national, regional, and select state-level 
data for the current and previous seasons, can be found at 
http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
▪ Influenza-like Illness State Activity Indicator Map: New York City, the District 
of Columbia, and 42 states experienced high ILI activity (Alabama, Alaska, Arizona, 
Arkansas, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, 
New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, 
South Carolina, South Dakota, Tennessee, Texas, Vermont, Virginia, West Virginia, 
Wisconsin, and Wyoming). Puerto Rico and two states (California and Idaho) 
experienced moderate ILI activity. Three states experienced low ILI activity 
(Delaware, North Dakota and Washington). Three states experienced minimal ILI 
activity (Maine, Montana, and Utah).  
 
o Additional data, including data for previous seasons, can be found at 
https://gis.cdc.gov/grasp/fluview/main.html  
▪ Geographic Spread of Influenza Viruses: Widespread influenza activity was 
reported by Puerto Rico and 48 states (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, 
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, 
Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New 
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, 
Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, 
Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, 
and Wyoming). Regional influenza activity was reported by Guam and one state 
(Oregon). Local influenza activity was reported by the District of Columbia and one 
state (Hawaii). Sporadic activity was reported by the U.S. Virgin Islands. 
Geographic spread data show how many areas within a state or territory are seeing 
flu activity. 
o Additional data are available at: https://gis.cdc.gov/grasp/fluview/FluView8.html. 
   
▪ Flu-Associated Hospitalizations: Since October 1, 2017, 14,676 laboratory-
confirmed influenza-associated hospitalizations have been reported through the 
Influenza Hospitalization Network (FluSurv-NET), a population-based surveillance 
network for laboratory-confirmed influenza-associated hospitalizations. This 
translates to a cumulative overall rate of 51.4 hospitalizations per 100,000 people 
in the United States.  
o The highest hospitalization rate is among people 65 years and older (226.8 
per 100,000), followed by adults aged 50-64 years (54.0 per 100,000), and 
younger children aged 0-4 years (33.3 per 100,000). During most seasons, 
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adults 65 years and older have the highest hospitalization rates, followed by 
children 0-4 years.  
o During 2014-2015, hospitalization rates reported during week 4 for all ages 
were 43.5 per 100,000. During that same week, hospitalization rates for 
people 65 years and older were 213.8 per 100,000. Hospitalization rates for 
younger children 0-4 years were 40.2 per 100,000. 
o Hospitalization data are collected from 13 states and represent approximately 
9% of the total U.S. population. The number of hospitalizations reported 
does not reflect the actual total number of influenza-associated 
hospitalizations in the United States. Additional data, including hospitalization 
rates during other influenza seasons, can be found at 
http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and 
http://gis.cdc.gov/grasp/fluview/FluHospChars.html.  
 
▪ Mortality Surveillance:  
o The proportion of deaths attributed to pneumonia and influenza (P&I) sharply 
increased again to 9.7% for the week ending January 13, 2018 (week 2). 
This percentage is above the epidemic threshold of 7.2% for week 2 in the 
National Center for Health Statistics (NCHS) Mortality Surveillance System.  
o Region and state-specific data are available at 
https://gis.cdc.gov/grasp/fluview/mortality.html.    
▪ Pediatric Deaths 
o 17 influenza-associated pediatric deaths were reported to CDC during week 
4. 
• Five deaths were associated with an influenza A(H3) virus and occurred 
during weeks 1, 2, 3, and 4 (the weeks ending January 6, January 13, 
January 20, and January 27, 2018).  Two deaths were associated with an 
influenza A(H1N1)pdm09 virus and occurred during weeks 3 and 4 (the 
weeks ending January 20, 2018, and January 27, 2018, respectively).  
Four deaths were associated with an influenza A virus for which no 
subtyping was performed and occurred during weeks 3 and 4.  Five 
deaths were associated with an influenza B virus and occurred during 
weeks 1, 3, and 4 (the week ending January 6, January 20, and January 
27, 2018, respectively).   
o A total of 53 influenza-associated pediatric deaths for the 2017-2018 flu season 
have been reported to CDC. 
• One influenza-associated pediatric death that occurred during the past 
2015-2016 flu season was reported to CDC during week 4.  
• This death was associated with an influenza A virus for which no 
subtyping was performed and occurred during week 28 (the week ending 
July 16, 2016).  This death brings the total number of reported influenza-
associated deaths occurring during that season to 93. 
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Additional information on pediatric deaths is available on FluView Interactive 
at: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.   
 
▪ Laboratory Data:  
o Nationally, the percentage of respiratory specimens testing positive for influenza 
viruses in clinical laboratories during the week ending January 27 was 
26.1%. 
o Regionally, the three week average percent of specimens testing positive for 
influenza in clinical laboratories ranged from 18.3% to 32.3%. 
o During the week ending January 27, of the 15,427 (26.1%) influenza-
positive tests reported to CDC by clinical laboratories, 11,792 (76.4%) were 
influenza A viruses and 3,635 (23.6%) were influenza B viruses. 
o The most frequently identified influenza virus subtype reported by public 
health laboratories was influenza A(H3N2) virus.   
o During the week ending January 27, 1,280 (80.2%) of the 1,597 influenza-
positive tests reported to CDC by public health laboratories were influenza A 
viruses and 317 (19.8%) were influenza B viruses. Of the 1,206 influenza A 
viruses that were subtyped, 1,017 (84.3%) were H3N2 viruses and 189 
(15.7%) were (H1N1)pdm09 viruses. 
o The majority of the influenza viruses collected from the United States during 
October 1, 2017 through January 27, 2018 were characterized antigenically 
and genetically as being similar to the cell-grown reference viruses 
representing the 2017–18 Northern Hemisphere influenza vaccine viruses. 
o Since October 1, 2017, CDC has tested 282 influenza A(H1N1)pdm09, 828 
influenza A(H3N2), and 337 influenza B viruses for resistance to antiviral 
medications (i.e. oseltamivir, zanamivir, or peramivir). While the majority of 
the tested viruses showed susceptibility to the antiviral drugs, two (0.7%) 
H1N1pdm09 viruses were resistant to both oseltamivir and peramivir, but 
was sensitive to zanamivir. 
FluView (http://www.cdc.gov/flu/weekly/fluactivitysurv.htm) is available – and past issues are 
archived (http://www.cdc.gov/flu/weekly/pastreports.htm) – on the CDC website. 
Note: Delays in reporting may mean that data changes over time. The most up to 
date data for all weeks during the 2017 Pediatric Deaths-2018 season can be found 
on the current FluView(http://www.cdc.gov/flu/weekly/) and FluView Interactive 
(https://www.cdc.gov/flu/weekly/fluviewinteractive.htm). 
 
Pediatric Deaths 
• Seventeen influenza-associated pediatric deaths were reported to CDC during week 
4 of the 2017-2018 season, one of which occurred during the 2015-2016 season. 
• Five deaths were associated with an influenza A(H3) virus occurred during weeks 1, 
2, 3, and 4 (the weeks ending January 6, January 13, January 20, and January 27, 
2018, respectively). 
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o Two deaths were associated with an influenza A(H1N1)pdm09 virus and 
occurred during weeks 3 and 4 (the weeks ending January 20, 2018, and 
January 27, 2018, respectively). 
o Four deaths were associated with an influenza A virus for which no subtyping 
was performed and occurred during weeks 3 and 4. 
o Five deaths were associated with an influenza B virus and occurred during 
weeks 1, 3, and 4 (the week ending January 6, January 20, and January 27, 
2018, respectively). 
• A total of 53 influenza-associated pediatric deaths have been reported for the 2017-
2018 season. 
• Since 2004, when pediatric deaths associated with influenza infection became 
nationally notifiable, the number of deaths reported to CDC each year has ranged 
from 37 (2011-2012 season) to 171 deaths (2012-2013 season). 
• Last season, 2016-2017, 110 influenza-associated pediatric deaths were reported 
to CDC. 
• During past seasons, approximately 80% of flu-associated deaths in children have 
occurred in children who were not vaccinated. Based on available data, this remains 
true for the 2017-2018 season, as well.  
• Since the 2010-2011, between 43.8% to 59% of pediatric deaths occurred in 
children who were otherwise healthy and didn’t have an underlying medical 
condition. 
• Because of confidentiality issues, CDC does not discuss or give details on 
individuals. 
• These deaths are a somber reminder of the danger flu poses to children. 
• The single best way to protect against seasonal flu and its potentially severe 
consequences in children is to get a seasonal flu vaccine each year. 
• Vaccination is important for children younger than 5 years. It is especially 
important for those younger than 2 years and children of any age with a long-term 
health condition like asthma, diabetes and heart disease and neurological and 
neurodevelopmental diseases. These children are at higher risk of serious flu 
complications if they get the flu. 
• Yearly vaccination also is especially important for people in contact with high risk 
children in order to protect the child (or children) in their lives from the flu. In 
particular, children younger than 6 months are too young to be vaccinated 
themselves but are at high risk of flu complications if they get sick so the people 
around them should get vaccinated to protect the infant. 
• Some children 6 months through 8 years of age require 2 doses of influenza 
vaccine. Children in this age group who are getting vaccinated for the first time will 
need two doses. Some children who have received influenza vaccine previously also 
will need two doses this season. A health care provider should be consulted to 
determine whether two doses are recommended for a child. 
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• Flu-associated deaths in children younger than 18 years old should be reported 
through the Influenza-Associated Pediatric Mortality Surveillance System. The 
number of flu-associated deaths among children reported during the 2017-2018 flu 
season will be updated each week and can be found at www.cdc.gov/flu/weekly/ 
and https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
